Pharming Group to participate in November investor conferences


Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of November:

  • Stifel 2023 Healthcare Conference, New York, November 14-15
    Anurag Relan, Chief Medical Officer will participate in a fireside chat, question and answer session on Tuesday, November 14 at 08:35 am ET/14:35 CET.
  • Jefferies London Healthcare Conference 2023, London, U.K., November 14-16
    Sijmen de Vries, Chief Executive Officer will present on Wednesday, November 15 at 08:30 GMT/09:30 CET.

For more information about these conferences, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or your Stifel or Jefferies representative.


About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696

Heather Robertson, Investor Relations & Corporate Communications Manager
E: [email protected]

FTI Consulting, London, UK

Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: [email protected]

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.